(paliperidone palmitate) modified release injectable suspension
The information contained in this learning resource contains a portion of the product information. For full details see the product information by each product owner. A full list can be found in the References tab.
Yes4
No4
150 mg on Day 1
100 mg on Day 8
*If the patient had never taken oral paliperidone or oral or injectable risperidone, it is recommended to establish tolerability with oral paliperidone or oral risperidone prior to initiating treatment with INVEGA SUSTENNA.
No4
Prefilled syringe
Shake the syringe containing INVEGA SUSTENNA for a minimum of 10 seconds to ensure a homogenous suspension.4
None stated in the PI
54
Single-dose, prefilled syringe kit
None stated in PI
75 mg
(some patients may benefit from lower or higher doses within the recommended range of 25 - 150 mg)
0.25 mL (39 mg dose) - 1.5 mL (234 mg dose):4
1, 1.54
22, 234
IM (deltoid or gluteal)4
For patients weighing less than 90 kg, the 1-inch, 23 gauge needle is recommended
For patients weighing 90 kg or more, the 1.5-inch, 22 gauge needle is recommended4
The recommended needle size for administration into the gluteal muscle is the 1.5-inch, 22 gauge needle regardless of patient weight4
n/a
Prefilled syringe
Single-dose, prefilled syringe kit
1 single-dose, prefilled syringe containing INVEGA SUSTENNA aqueous suspension with backstop, a plunger stopper, and tip cap
+
2 safety needles to choose from for drug administration4
No4
Store below 25°C
None stated in PI
Not stated in PI
Not stated in PI
Room Temperature4
Shake the syringe containing INVEGA SUSTENNA for a minimum of 10 seconds to ensure a homogenous suspension.4
None stated in the PI
By clicking the button below you agree to the following:
I understand that S.C.O.P.E. is for educational purposes only and not to be used for the treatment or diagnosis of schizophrenia, nor is it a substitute for clinical judgment or guidelines.